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In Parkinson’s disease (PD), misfolded and aggregated α-synuclein protein accumulates in degenerating midbrain dopaminergic
neurons. The amino acid alanine-76 in α-synuclein and phosphorylation at serine-87 and serine-129 are thought to regulate its
aggregation and toxicity. However, their exact contributions to α-synuclein membrane association are less clear. We found that α-
synuclein is indeed phosphorylated in ﬁssion yeast and budding yeast, the two models that we employed for assessing α-synuclein
aggregation and membrane association properties, respectively. Surprisingly, blocking serine phosphorylation (S87A, S129A, and
S87A/S129A) or mimicking it (S87D, S129D) altered α-synuclein aggregation in ﬁssion yeast. Either blocking or mimicking
this phosphorylation increased endomembrane association in ﬁssion yeast, but only mimicking it decreased plasma membrane
association in budding yeast. Polar substitution mutations of alanine-76 (A76E and A76R) decreased α-synuclein membrane
association in budding yeast and decreased aggregation in ﬁssion yeast. These yeast studies extend our understanding of serine
phosphorylation and alanine-76 contributions to α-synuclein aggregation and are the ﬁrst to detail their impact on α-synuclein’s
plasma membrane and endomembrane association.
1.Introduction
The α-synucleinopathies are a group of neurodegenerative
diseases that include Parkinson’s disease, dementia with
Lewy bodies (DLB), multiple system atrophy (MSA), and
Lewy body dysphagia [1–4]. Each disease is characterized by
neuronal death and accumulation of α-synuclein and several
other proteins in cytoplasmic inclusions called Lewy bodies
[5]. Of these, PD is the most prevalent disorder, aﬄicting
over 4 million people worldwide [6]. While whether the
aggregation of α-synuclein is neurotoxic or a protective cel-
lular response is still being resolved, α-synuclein is intimately
linked to pathogenesis as Lewy bodies are found in both
sporadic and familial PD, and three point mutations (A53T,
A30P, and E46K) within the α-synuclein gene itself cause PD
[7–9]. Duplication or triplication of the α-synuclein locus
also results in PD onset, further implicating α-synuclein
in PD pathogenesis [10, 11]. Even sporadic PD is linked
to polymorphisms in the α-synuclein gene that potentially
increase protein production [12].
α-Synuclein is a short, highly ﬂexible protein found
throughout the brain and localized to presynaptic terminals
of dopaminergic neurons [13–15]. Two biochemical prop-
erties of α-synuclein most clearly linked to PD pathology
are intracellular aggregation [16] and membrane association
[17],buthoweachcontributestocellulartoxicityisstillbeing
sorted. Additionally, several factors are thought to inﬂuence
both these α-synuclein properties, including posttransla-
tional modiﬁcations such as ubiquitination [18], glycosyla-
tion [18], nitration [18–20], and phosphorylation [21, 22],
as well as speciﬁc amino acids within the protein’s three
domains, especially its middle NAC domain [19, 23, 24].
This study speciﬁcally focused on the amino acid alanine-76
within the NAC domain and on serine phosphorylation.
Within Lewy bodies, α-synuclein is heavily phosphory-
lated at serine-129 and serine-87 [21, 22, 25] .T h er o l eo f
phosphorylation has been studied in several model systems
with conﬂicting ﬁndings [22, 26–30]. A study in ﬂies found
that phosphorylation enhanced α-synuclein toxicity [27],2 Parkinson’s Disease
while other research in mice and rats concluded that phos-
phorylation was neuroprotective [28, 29]. Still another study
in rats saw no change in toxicity due to phosphorylation
[30]. Additionally, some work suggests that phosphorylation
enhances aggregation [22, 26, 28], while others suggest that
aggregation decreases when α-synuclein is phosphorylated
[25, 27, 30]. The link between membrane association and
phosphorylation is considerably less well studied, with only
a single in vitro study suggesting that serine-87 phosphory-
lation inhibits membrane association [25]. More research is
needed to clarify the role of serine phosphorylation in α-
synuclein toxicity, aggregation, and membrane association.
α-Synuclein is comprised of three domains that con-
tribute diﬀerentially to the protein’s properties. The amino
domain (1-60) forms an amphipathic α-helix upon binding
to lipids [31]. The NAC domain (61-95) is highly amy-
loidogenic and mostly closely linked to aggregation and
ﬁbrilformation[32].Thecarboxyldomain(96-140)opposes
aggregation and is typically truncated in Lewy bodies [33].
α-Synuclein has a natural tendency to aggregate due to its
ﬂexible structure [34], and the NAC domain of α-synuclein
is needed for this aggregation [13, 32, 35, 36]. Deletion of
amino acids 71–82 within the NAC domain signiﬁcantly
decreases α-synuclein aggregation in vitro [19, 37] and in
cell culture [38]. Within this domain, alanine-76 has been
mathematically predicted to contribute to aggregation of the
protein [23], and the combined deletion of alanine-76 and
valine-77 reduces the formation of aggregates in vitro [37].
However,thecontributionsofalanine-76toaggregationhave
not been assessed in other organismal models, especially
yeast, where contributions to membrane association can
additionally be evaluated.
A number of successful budding yeast (Saccharomyces
cerevisiae) model systems for α-synuclein aggregation, mem-
brane association, and toxicity have been established since
2003 [38–44]. Additionally, our lab pioneered a ﬁssion
yeast α-synuclein model in 2006, marking the ﬁrst time
Schizosaccharomyces pombe had been used to model PD-
associated α-synuclein properties [45]. These two yeast sys-
temsprovideauniqueresearchopportunitytocomparatively
study how α-synuclein exhibits aggregation and membrane
associationpropertiesineachorganism.Inbuddingyeast,we
and others ﬁnd that α-synuclein associates with the plasma
membranewhenexpressedatmoderatelevels[38,40–42].In
ﬁssion yeast, we reported that α-synuclein forms aggregate-
like inclusions within the yeast cell in a concentration-
dependent manner, but it rarely associates with the plasma
membrane [45]. Thus, each yeast model recapitulates an
important PD-related property of α-synuclein (aggregation
or membrane association), allowing us to determine how
serine phosphorylation and alanine-76 impact these two
pathologically linked properties of α-synuclein.
In this study, we hypothesized that phosphoryla-
tion contributes to membrane association of α-synuclein,
which we tested by generating phosphorylation-deﬁcient
(S87A, S129A, and S87A/S129A) and phosphorylation-
mimic (S87D and S129D) α-synuclein mutants. We also
created nonpolar to polar (A76E and A76R) α-synuclein
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Figure 1: WT α-synuclein is phosphorylated at serine-129 in
both yeasts. Western blot of BY4741 WT and TCP1WT lysates
probed with anti-pS129 (top), anti-V5 (α-synuclein; middle), and
protein loading control anti-β-actin (bottom). WT α-synuclein is
phosphorylated at serine-129 in both yeasts.
mutants to evaluate alanine-76’s contributions to mem-
brane association. We report that serine phosphorylation
altered α-synuclein’s interaction with membrane systems:
endomembrane structures of ﬁssion yeast and the plasma
membrane in budding yeast. We also found that alanine-76
contributed signiﬁcantly to α-synuclein membrane associa-
tion in budding yeast and regulated α-synuclein aggregation
in ﬁssion yeast. Neither serine phosphorylation nor alanine-
76 signiﬁcantly aﬀected toxicity in either yeast model.
2. Results
2.1. Wild-Type α-Synuclein Is Phosphorylated in Both Yeast
Models. To date, only one study has reported that wild-
type (WT) α-synuclein is phosphorylated in a budding
yeast model for studying PD-related properties [46], but
none have been reported for ﬁssion yeast. An antibody is
readily available for serine-129 phosphorylated α-synuclein
(ab59264; Abcam), but not for phosphorylation at serine-
87, so we probed lysates from BY4741 budding yeast and
TCP1 ﬁssion yeast cells expressing WT α-synuclein with this
anti-pS129 antibody. The Western blot showed that WT α-
synucleinisphosphorylatedatserine-129ineachofouryeast
models (Figure 1).
2.2. Phosphorylation Mutants Alter α-Synuclein Localization
in Fission Yeast in Complex Ways. We ﬁrst assessed our
phosphorylation mutants in ﬁssion yeasts, which best reca-
pitulates α-synuclein aggregation [45]. We referred to the α-
synucleinlocalizationpatterninﬁssionyeastsas“aggregates”
in our initial study [45] and do so again here, as they are
distinct intracellular accumulations that are diﬀerent from
the plasma membrane or the vesicular membrane localiza-
tion of α-synuclein-GFP in budding yeast. We acknowledgeParkinson’s Disease 3
thatforthesepunctatobedeﬁnedastrueaggregateselectron
microscopy is required and that is an experiment that we
haveyettoperform.Usingtheanti-pS129antibody,wedeter-
mined that WT and S87A α-synuclein were phosphorylated
at serine-129 while S129A was not (Figure 2(a)). S87D was
also phosphorylated at S129, but S129D was not, indicating
that the antibody recognizes the phosphate group added to
serine-129 rather than the overall shape of phosphorylated
α-synuclein (Figure 2(a)). As expected, the antibody did not
recognize the double mutant S87A/S129A (Figure 2(a)). An
antibody for V5 shows that mutants and WT α-synuclein
were all expressed (Figure 2(a)).
We then assessed if our phosphorylation mutants
altered α-synuclein aggregation, the phenotype we previ-
ously reported in ﬁssion yeast [45]. The phosphorylation-
deﬁcient mutants decreased α-synuclein aggregation at both
24 and 48 hours of expression (Figure 2(b),t o p ) .I n s t e a d ,
thephosphorylation-deﬁcient mutantsenhancedassociation
with intracellular membranous, especially perinuclear, com-
partments, with over 90% of ﬂuorescing cells exhibiting
this phenotype (Figure 2(b)-bottom). The phosphorylation-
mimic mutants also altered α-synuclein localization: S87D
α-synucleinincreasedlocalizedtothecytoplasm(15%)com-
p a r e dt oW T( 0 % )i nﬁ s s i o ny e a s ta t2 4h o u r s( Figure 2(b)-
bottom), while S129D α-synuclein demonstrated a pattern
surprisingly similar to phosphorylation-deﬁcient mutants at
24 hours but became aggregated similar to WT α-synuclein
levels by 48 hours (Figure 2(b)-bottom).
Lastly, given the signiﬁcant impact on α-synuclein
aggregation, we examined whether the phosphorylation
mutants modiﬁed α-synuclein toxicity in ﬁssion yeast where
WT α-synuclein is itself moderately toxic (Fiske et al.,
2011, in press ISRN Neurology). We assessed ﬁvefold
serial dilution spotting and found that surprisingly neither
the phosphorylation-mimic nor phosphorylation-deﬁcient
mutants altered the level of toxicity already exhibited by WT
α-synuclein (Figure 2(c)).
2.3. Phosphorylation Mutants Slightly Alter α-Synuclein Mem-
brane Binding in Budding Yeast. Whether serine phospho-
rylation regulates α-synuclein membrane association has
not previously been reported. Therefore, we next assessed
phosphorylation mutants in our budding yeast model,
whereWTα-synucleinassociateswiththeplasmamembrane
when expressed at moderate levels [41]. We ﬁrst examined
phosphorylation status and expression with the anti-pS129
antibody. WT and S87A α-synuclein were phosphorylated at
serine-129 while the S129A mutant was not (Figure 3(a)),
just as seen in ﬁssion yeast. S87D α-synuclein was also phos-
phorylated at serine-129, but the S129D phosphorylation-
mimic mutant was not (Figure 3(a)). V5 immunoblotting
shows that phosphorylation mutants and WT α-synuclein
were expressed in all cells (Figure 3(a)).
Next, we evaluated where the phosphorylation mutants
localized relative to WT α-synuclein in budding yeast.
All phosphorylation-deﬁcient α-synuclein mutants localized
primarily to the plasma membrane of cells at 24 and 48
hours(85%ofcells),asindicatedbylive-cellGFPmicroscopy
and quantiﬁcation (Figure 3(b)). In contrast, more than
half the cells expressing phosphorylation-mimic mutants
localized α-synuclein to the cytoplasm at 24 hours (66%
for S87D α-synuclein and 57% for S129D α-synuclein).
By 48 hours, however, S87D and S129D α-synuclein local-
ized to the plasma membrane (70%), almost to WT α-
synuclein and the phosphorylation-deﬁcient mutants levels
(Figure 3(b)). Therefore, the cytoplasmic localization of the
phosphorylation-mimic mutants was temporary.
Lastly,giventhismoderateimpactofphosphorylationon
membrane association, we assessed whether it was enough
to regulate cellular toxicity. Previously, we reported that WT
α-synuclein was not toxic to budding yeast ([41]; and Fiske
et al. in press ISRN Neurology). Serial dilution spotting on
solid plate media revealed no change in growth of budding
yeast cells expressing any of the α-synuclein phosphorylation
mutants in comparison to cells expressing the empty vector,
GFP, or WT α-synuclein (Figure 3(c)).
2.4. A76E and A76R Mutants Diﬀerentially Alter α-Synuclein
Localization in Fission Yeast. We next sought to characterize
alanine-76 in our yeast models by examining the A76E
and A76R mutants in ﬁssion yeast. Both mutants altered
α-synuclein aggregation patterns. Compared to WT α-
synuclein, A76E α-synuclein strongly localized throughout
the cytoplasm of the ﬁssion yeast cells (78%) with only
minorintracellularpunctaformingby24hoursofexpression
(Figure 4(a)-right). It remained in the cytoplasm after 48
hours (71%), although more prominent aggregates formed
by this time. A76R α-synuclein also localized to the cyto-
plasm by 24 hours (68%), but some cells began to exhibit
endomembrane localization (Figure 4(a)). By 48 hours, this
A76R endomembrane localization pattern became even
more prominent, and diﬀerent from the kind of aggregates
seen with WT and A76E α-synuclein. Unexpectedly, some α-
synuclein plasma membrane association was also apparent
at 24 and 48 hours with A76R α-synuclein (Figure 4(a)-left),
suggesting that this mutant might actually confer aﬃnity for
plasma membranes.
Next, we determined whether the A76E and A76R
mutants altered WT α-synuclein level of toxicity in ﬁssion
yeast. Fivefold serial dilution spotting revealed no change in
growth between cells expressing WT α-synuclein and the two
alanine-76 mutants (Figure 4(b)).
Lastly, we assessed α-synuclein expression levels in cells
expressing WT, A76E, or A76R α-synuclein. No signiﬁcant
diﬀerence in expression was observed in cells expressing WT,
A76E, or A76R α- s y n u c l e i na t2 4o r4 8h o u r s( Figure 4(c)).
2.5. Alanine-76 Mutants Alter Localization in Budding Yeast
without Inducing Toxicity. Finally, we characterized alanine-
76 eﬀects on plasma membrane association by studying the
A76E and A76R mutants in budding yeast. Indeed, both
A76E and A76R α-synuclein increased localization to the
cytoplasm of the yeast at 24 hours after induction (60%),
although many cells retained some membrane association
as well (Figure 5(a)-right). However, unlike A76E, which
remained in the cytoplasm (62%), the A76R α-synuclein4 Parkinson’s Disease
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Figure 2: Characterization of phosphorylation mutants in TCP1. (a) Western blot of WT, phosphorylation-deﬁcient mutants (S87A,
S129A, and S87A/S129A), and phosphorylation-mimic mutants (S87D, S129D). TCP1 lysates were probed with anti-pS129 (top), anti-
V5 (α-synuclein; middle), and anti-β-actin (bottom) (N = 3). (b) Live-cell GFP microscopy of TCP1 cells expressing GFP, WT, S87A,
S129A, S87A/S129A, S87D, or S129D at 24 and 48 hours (top). Quantiﬁcation: ∼7 5 0c e l l so fe a c ht y p ew e r es c o r e df o rt h e s el o c a l i z a t i o n
patterns: cytoplasmically diﬀuse, aggregate, endomembrane, endomembrane/diﬀuse, and endomembrane/aggregate (bottom). Phenotypes
were plotted as a percent of total cells that ﬂuoresced (N = 2). (c) Cells expressing WT, S87A, S129A, S87A/S129A, S87D, or S129D were
grown in inducing (EMM−T) media for 48 hours. Vector alone and GFP served as controls. Equal number of cells were serially diluted
5-fold and spotted onto repressing (EMM+T) or inducing (EMM−T) plates and grown for two days (bottom). No phosphorylation-speciﬁc
toxicity was apparent in either assay (N = 3).Parkinson’s Disease 5
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Figure 3: Characterization of phosphorylation mutants in BY4741. (a) Western blot of WT, phosphorylation-deﬁcient mutants (S87A,
S129A, and S87A/S129A), and phosphorylation-mimic mutants (S87D, S129D). BY4741 lysates were probed with anti-pS129 (top), anti-
V5 (α-synuclein; middle), and anti-PGK, which served as a protein-loading control (bottom). WT, S87A, and S87D are phosphorylated at
serine-129 (N = 2). (b) Live-cell GFP microscopy of BY4741 cells expressing GFP, WT, S87A, S129A, S87A/S129A, S87D, or S129D at 24
and 48 hours (top). Quantiﬁcation: ∼750 cells of each type were scored for these localization patterns: cytoplasmically diﬀuse, and plasma
membrane, aggregate, plasma membrane/diﬀuse, plasma membrane/aggregate (bottom). Phenotypes were plotted as a percent of total cells
that ﬂuoresced (N = 2). (c) Cells expressing WT, S87A, S129A, S87A/S129A, S87D, or S129D were grown in inducing (galactose) media for
48 hours. Vector alone and GFP served as controls. Equal number of cells were serially diluted 5-fold and spotted onto repressing (glucose)
or inducing (galactose) plates and grown for two days (bottom). No phosphorylation-speciﬁc toxicity was apparent (N = 3).6 Parkinson’s Disease
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Figure 4: Characterization of alanine-76 in TCP1. (a) Live-cell GFP microscopy of TCP1 cells expressing WT, A76E, or A76R at 24 and
48 hours (left). Quantiﬁcation: ∼750 cells of each type were scored for these localization patterns: diﬀuse, aggregate, and aggregate/diﬀuse
(right). Phenotypes were plotted as a percent of total cells that ﬂuoresced (N = 2). (b) TCP1 cells expressing WT, A76E, or A76R were grown
in inducing (EMM−T) media for 48 hours. Vector alone and GFP served as controls. Equal number of cells were serially diluted 5-fold
and spotted onto repressing (EMM+T) or inducing (EMM−T) plates and grown for two days (right). The A76E and A76R mutants were
equally toxic as WT (N = 3). (c) Western blot of TCP1 cells expressing WT, A76E, or A76R at 24 and 48 hours. Lysates were probed with
anti-V5(α-synuclein)oranti-β-actin(loadingcontrol).ExpressionisequivalentbetweenWTandthealanine-76mutantsat24and48hours
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localized back to the plasma membrane by 48 hours (77%;
Figure 5(a)).
We next evaluated how the alanine-76 mutants altered
the toxic properties of α-synuclein in budding yeast. Five-
foldserialdilution spotting indicatedthatbudding yeastcells
expressingA76EorA76RgrewjustaswellasWTα-synuclein
cells (Figure 5(b)).
We lastly determined how α-synuclein expression levels
changed in the budding yeast as a result of the A76E or A76R
mutations. Western blot illustrated no evident diﬀerence in
expression levels at 24 or 48 hours between cells expressing
WT, A76E, or A76R α-synuclein (Figure 5(c)).
3. Discussion
Both serine phosphorylation on α-synuclein and alanine-76
(within its NAC domain) have been implicated in altering α-
synuclein aggregation and toxicity, but less so in regulating
membrane association. Studies examining serine phospho-
rylation in diﬀerent model organisms have produced con-
ﬂicting results, and alanine-76 studies have not yet been well
recapitulated in a free-living organism. Here, we show that
both serine phosphorylation and alanine-76 signiﬁcantly
regulate the membrane association and aggregation of the
protein. We discuss three main ﬁndings: (1) α-synuclein is
phosphorylated at serine-129 in both budding yeast and
ﬁssion yeast; (2) phosphorylation contributes signiﬁcantly
to aggregation but only moderately impacts membrane
association; (3) alanine-76 is relevant to both aggregation
and membrane association.
3.1. α-Synuclein Is Phosphorylated at Serine-129 in Budding
and Fission Yeasts. Western blotting with the anti-pS129
antibody demonstrates that serine-129 on α-synuclein is
phosphorylatedinbothofouryeastmodels.Whetherserine-
87 phosphorylation occurs in yeasts still remains to be
determined. Our data conﬁrms an initial report in budding
yeast [46] and extends it to ﬁssion yeast that yeasts possess
protein kinases that can phosphorylate human α-synuclein.
Identifying the yeast protein kinase(s) may facilitate progress
if α-synuclein phosphorylation is, in fact, pathogenic and
if human kinase homologues exist. Previous studies have
shown that α-synuclein is phosphorylated in human cell
culture [21], transgenic Drosophila [47], and transfected
rats [48]a n dm i c e[ 49]. Several kinases have demonstrated
the potential to phosphorylate α-synuclein at serine-129 in
vitro, including casein kinase I and II [21, 48], G protein-
coupled receptor kinases 1, 2, 5, and 6 [50], LRRK2 [51],
and the polo-like kinases [52, 53]. However, the identity
of the kinases responsible for serine-129 and serine-87
phosphorylation in Lewy bodies is still unknown.
3.2. Phosphorylation Status Regulates Aggregation and Mem-
brane Association. α-Synuclein forms intracellular aggre-
gates in our ﬁssion yeast model [45]. These could either be
true Lewy body-like inclusions or they could be intracellular
membranous structures derived from the secretory pathway
that have coalesced together. Our data indicates that α-
synuclein serine phosphorylation does regulate α-synuclein
aggregation as both constitutive phosphorylation and the
lack of it signiﬁcantly alter the α-synuclein aggregation
pattern. Therefore, we suggest that the intracellular con-
centration of phosphorylated α-synuclein helps determine
whether the protein aggregates, bind membranes, or remain
cytoplasmically diﬀuse, and this complex relationship is
likely cell/organismal speciﬁc. It may partly explain why
several past studies that have investigated serine phosphory-
lation’s role in α- s y n u c l e i na g g r e g a t i o na n dt o x i c i t yh a v en o t
found consistent results across organismal models [22, 26–
28, 30].
This is the ﬁrst study to demonstrate phosphorylation’s
role in altering α-synuclein’s interaction with endomem-
branes and with the plasma membrane, providing live-cell
support for past in vitro demonstration that serine phospho-
rylation decreases membrane association [25]. Speciﬁcally,
in ﬁssion yeast, blocking serine phosphorylation enhances α-
synuclein to endomembrane structures, most likely due to
resdistribution of α-synuclein that is now less aggregated. In
budding yeast, constitutive serine phosphorylation decreases
α-synucleinplasmamembraneassociation,atleastintheﬁrst
24 hours. The diﬀerences between the yeasts could be due
to α-synucleinassociatingdiﬀerentlywithplasmamembrane
than it does diverse endomembrane structures, and this
could be the result of diﬀerential phospholipid interactions
and/or associations with membrane-speciﬁc proteins that
may be cell/organismal dependent.
3.3. Alanine-76 Regulates Membrane Association and Aggre-
gation. In support of our hypothesis, both A76E and A76R
α-synuclein mutants decrease plasma membrane association
in budding yeast and decrease aggregation in ﬁssion yeast,
but to diﬀering extents, emphasizing the critical importance
of this amino acid initially indicated in vitro and in cell
culture [19, 54]. More recently, deletions of alanine-76
and alanine-77 decreased maturation of α-synuclein ﬁbril
formation and increased oligomerization [37]. Future work
should aim to identify other amino acids that contribute
signiﬁcantly to the biochemical properties of α-synuclein.
In ﬁssion yeast, neither WT nor A30P and A53T familial
synuclein PD mutants associate with its plasma membrane
[45],butA76Rdoes,whichsuggeststhatspeciﬁcallylocalized
positively charged amino acids might help drive α-synuclein
membrane association. In support of this notion, the
E46K synuclein familial PD mutant (with its lysine charge)
extensively and selectively associates with endomembrane
structures in some ﬁssion yeast strains and associates more
strongly than WT and A53T synuclein with the plasma
membrane in budding yeast (Fiske et al., manuscript in press
ISRN Neurology).
3.4. Lack of Toxicity. The exact link between serine phos-
phorylation of α-synuclein and neurotoxicity is contro-
versial. Some studies support more phosphorylation [27],
while others support less phosphorylation [28, 29]o rﬁ n d
no link at all [30]. Our ﬁndings in yeasts support the8 Parkinson’s Disease
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Figure 5: Characterization of alanine-76 in BY4741. (a) Live-cell GFP microscopy of BY4741 cells expressing WT, A76E, or A76R at 24
and 48 hours (left). Quantiﬁcation: ∼750 cells of each type were scored for these localization patterns: cytoplasmically diﬀuse, and plasma
membrane, aggregate, plasma membrane/diﬀuse, plasma membrane/aggregate (right). Phenotypes were plotted as a percent of total cells
thatﬂuoresced(N = 2).(b)BY4741cellsexpressingWT,A76E,orA76Rweregrownininducing(galactose)mediafor48hours.Vectoralone
and GFP served as controls. Equal number of cells were serially diluted 5-fold and spotted onto repressing (glucose) or inducing (galactose)
plates and grown for two days (right). No toxicity was apparent in budding yeast (N = 3). (c) Western blot of BY4741 cells expressing WT,
A76E, or A76R at 24 and 48 hours. Lysates were probed with anti-V5 (α-synuclein) or anti-PGK. Expression is equivalent between WT and
the alanine-76 mutants at 24 and 48 hours.Parkinson’s Disease 9
notion that α-synuclein serine phosphorylation does not
signiﬁcantly inﬂuence toxicity. It surprised us that, despite
the variety of α-synuclein localization phenotypes induced
with phosphorylation-mimic or phosphorylation-deﬁcient
mutants in both yeasts, none of these changes induced
toxicity. Recent evidence has suggested that phosphorylation
might promote the formation of protective, mature ﬁbrils
rather than the potentially toxic intermediates [31]. Perhaps
in our yeast models, enough toxic intermediates did not
build up with any of our phosphorylation mutants. Addi-
tionally, opposing inﬂuences of tyrosine phosphorylation
andserinephosphorylationonα-synuclein-dependenttoxic-
ityhavebeenproposed[55],whichmayhavemaskedtoxicity
resulting from mimicking or blocking serine phosphoryla-
tion.
Several lines of evidence also support the notion that
aggregation is a protective mechanism employed by cells
to prevent α-synuclein toxicity. For example, the A30P
familial mutant promotes the formation of protoﬁbrils
rather than mature amyloid ﬁbrils [56, 57], and these toxic
protoﬁbrils coincide with the fragmentation of the Golgi
apparatus and loss of cell viability in a cell culture model
[58]. If aggregates are protective, then reducing aggregation
should increase α-synuclein-dependent toxicity, but both
A76E and A76R mutants decreased aggregation in ﬁssion
yeast without increasing toxicity, suggesting that either not
enough toxic protoﬁbrils were generated or residual aggre-
gation provided enough protection. Several labs, including
ours, have suggested that membrane association is also a
contributing factor to α-synuclein toxicity [41, 59]. Yet,
increased endomembrane interactions or decreased plasma
membrane interactions exhibited by alanine-76 and/or spe-
ciﬁc phosphorylation mutants do not alter toxicity in either
yeast model. One reason could simply be that our budding
yeast model might not express suﬃcient levels of α-synuclein
to induce toxicity or that, in both yeasts, one or more
other cellular factors pathways need to be further comprised
[39], which include oxidative defense [41], proteasome [41],
ER/Golgi Pathway [42], endocytosis ([60]; Perez et al.,
manuscript in preparation), or autophagy (Konnikova et al.,
manuscript in preparation).
4.MaterialsandMethods
4.1. α-Synuclein Constructs. Wild-type (WT) α-synuclein-
GFP in pYES2.1/V5-His-TOPO budding yeast expression
vector (Invitrogen) or pNMT1/V5-His-TOPO was prepared
as described by Fiske et al. (manuscript current in press
withISRNNeurology). Thealanine-76andphosphorylation
mutants were created using site-directed mutagenesis (Invit-
rogen) with the above α-synuclein-GFP vectors as templates,
using the following primers:
A76E FP: 5  ATGTAGGCTCCAAAAACAAGAAGG-
GAGTGGTGC 3 
A76E RP: 5  CTTGGTTTTGGAGCCTACATAGAG-
AACACC 3 
A76R FP: 5  ATGTAGGCTCCAAAAACAAGAAGG-
GAGTGGTGC 3 
A76R RP: 5  CTTGGTTTTGGAGCCTACATAGAG-
AACACC 3 
S87A FP: 5  ATGTAGGCTCCAAAAACAAGAAGG-
GAGTGGTGC 3 
S87A RP: 5  CTTGGTTTTGGAGCCTACATAGAG-
AACACC 3 
S87D FP: 5  ATGTAGGCTCCAAAAACAAGAAGG-
GAGTGGTGC 3 
S87D RP: 5  CTTGGTTTTGGAGCCTACATAGAG-
AACACC 3 
S129A FP: 5  ATGTAGGCTCCAAAAACAAGA-
AGGGAGTGGTGC 3 
S129A RP: 5  CTTGGTTTTGGAGCCTACATA-
GAGAACACC 3 
S129D FP: 5  ATGTAGGCTCCAAAAACAAGA-
AGGGAGTGGTGC 3 
S129D RP: 5  CTTGGTTTTGGAGCCTACATA-
GAGAACACC 3 
The S87A/S129A mutant was created by ﬁrst making
the S87A mutant, which was then the template to make
the S129A mutation. Mutations were sequenced at Uni-
versity of Chicago to conﬁrm successful substitution. The
parent pYES2.1 vector for budding yeast (Invitrogen) and
parent pNMT1 pREP vector (gift from Judy Potashkin,
Rosalind Franklin University of medicine and sciences,
North Chicago, IL, USA) were controls.
4.2. Yeast Strains. Parent budding yeast strain was BY4741
(MATa his3Δ1l e u 2 Δ0m e t 1 5 Δ0u r a 3 Δ0), BY4742 (MATα
his3Δ1l e u 2 Δ0l y s 2 Δ0m e t 1 5 Δ0u r a 3Δ0), and BY4743
(MATa/α his3Δ1l e u 2 Δ0l y s 2 Δ0u r a 3 Δ0). Fission yeast strains
TCP1 (h- leu1-32) and SP3 (h+ leu1-32)w e r ep r o v i d e db y
Invitrogen and Judy Potashkin (Rosalind Franklin University
of Medicine and Science), respectively.
4.3. S. cerevisiae α-Synuclein Expression. α-Synuclein expres-
sion plasmid vectors were transformed into yeast strains as
described in [41]. For selection, yeasts cells were grown on
synthetic-complete media lacking uracil (SC-Ura). In the
pYES2vector,α-synucleinexpressionwascontrolledthrough
a tightly regulated galactose-inducible promoter (Gal1).
Yeast were grown to mid-log phase in SC-Ura glucose (2%)
or SC-Ura raﬃnose (2%) media at 30◦C. Cells were washed
with water and diluted to log-phase (5×106 cells/mL) in SC-
Ura galactose (2%) media to induce α-synuclein expression.
4.4. S. pombe α-Synuclein Expression. S. pombe strains were
transformed with pNMT1 vectors using the lithium-acetate
transformationmethod[45].Transformedcellswereselected
by growth on pombe dropout medium-leucine (PDM-Leu)
containing 10μM thiamine. α-Synuclein was expressed by
growth in thiamine-lacking media as described in [44].
4.5. Western Analysis. Budding or ﬁssion yeast cells at
2.5 × 107 cells/mL concentration were washed twice with10 Parkinson’s Disease
100mM NaN3 and solubilized in electrophoresis sample
buﬀer (ESB) [46]. The ESB contained 2% sodium dodecyl
sulfate (SDS), 80mM Tris (Ph 6.8), 10% glycerol, 1.5%
dithiothreitol, 1mg/mL bromophenol blue, and a cocktail
of protease inhibitors and solubilizing agents (1% Triton-
X 100, 1mM phenylmethylsulfonyl ﬂuoride, 1mM benza-
midine, 1mM sodium orthovanadate, 0.7mg/mL pepstatin
A, 0.5mg/mL leupeptin, 10mg/mL E64, 2 mg/ml aprotinin,
and 2mg/mL chymostatin). Lysates were electrophoresed
at 130 volts on a 10–20% Tris-Glycine gel (Invitrogen)
with 1X SDS running buﬀer. SeeBlue (Invitrogen) molecular
ladder was used as a standard. Gels were transferred to
PVDF membranes using a semidry transfer method and
probed using the desired antibodies. To detect α-synuclein,
a mouse monoclonal anti-V5-AP antibody (Invitrogen) was
used at 1:2000. Mouse antiphosphoglycerokinase (PGK;
molecular probes) was used at 1:1000 as a loading control
for budding yeast, and anti-β-actin (Abcam) was used at
1:1000 as a loading control for ﬁssion yeast. For both,
goat antimouse secondary antibody (Invitrogen) was used.
Serine-129 phosphorylation blots were probed with a rabbit
α-synuclein (phospho S129) antibody (ab59264; Abcam) at
1:500, followed by a goat antirabbit secondary antibody
(Santa Cruz Biotechnology). All blots were visualized by
detecting for alkaline-phosphatase activity. All blots were
done at least three times.
4.6. OD600 Growth Curve Analysis. Yeast cells were grown in
either 10mL SC-Ura + glucose (budding yeast) or EMM+T
(ﬁssionyeast)overnightat30◦Cand200rpm.Tocollectcells,
yeast were pelleted at 1500×gf o r5m i n u t e sa t4 ◦C. They
were washed twice with 5mL H2O, resuspended in 10mL
H2O, and counted using a hemocytometer to determine
cell density. Flasks containing 25 mL SC-Ura + galactose
(budding yeast) or EMM−T (ﬁssion yeast) were inoculated
to a density of 2.0 × 106 cells/mL. Duplicate spectropho-
tometer 600nm absorbance measurements of 1mL of cells
in a plastic cuvette were taken at 0, 3, 6, 12, 18, 24, 36,
and 48 hours after-induction. The spectrophotometer model
was a Hitachi U-2000 Spectrophotometer. A growth curve
was generated in Microsoft Excel by plotting the average
absorbance readings of three experiments. A Student’s t-test
was used to determine signiﬁcance.
4.7. Serial Dilution Spotting. Yeast cells were grown in either
10mLSC-Ura+glucose(buddingyeast)orEMM+T(ﬁssion
yeast) overnight at 30◦C and 200rpm. To collect cells,
yeasts were pelleted at 1500×gf o r5m i n u t e sa t4 ◦C. They
were washed twice with 5mL H2O, resuspended in 10mL
H2O, and counted using a hemocytometer to determine
cell density. 2.0 × 106 c e l l sw e r er e m o v e da n dp e l l e t e d .T h e
supernatant was removed, and cells were resuspended in
1mLH 2O. Cells were diluted 5-fold in a 96-well microtiter
plate and spotted onto SC-Ura + glucose and Sc-Ura +
galactose (budding yeast) or EMM+T and EMM−T (ﬁssion
yeast) growth plates. Cells were grown for 24 hours, and
pictures were taken using an HP CanoScan scanner. Images
were imported into Adobe Photoshop CS2. All spotting
experiments were conducted at least three times in triplicate.
4.8. GFP Microscopy. Yeast cells were grown in either 10 mL
SC-Ura + glucose (budding yeast) or EMM+T (ﬁssion yeast)
overnight at 30◦C and 200rpm. To collect cells, yeasts were
pelleted at 1500×gf o r5m i n u t e sa t4 ◦C. They were washed
twice with 5mL H2O, resuspended in 10 mL H2O, and
counted using a hemocytometer to determine cell density.
Flasks containing 25mL SC-Ura + galactose (budding yeast)
or EMM−T (ﬁssion yeast) were inoculated to a density
of 2.0 × 107 cells/mL. 1mL of cell culture was pelleted at
5000rpm for 1 minute. 900μL of supernatant was removed.
The remaining 100μLo fc e l lc u l t u r ew a sv o r t e x e d ,a n d5 –
10μL of sample was pipetted onto a glass slide. Cells were
visualized using a Nikon TE2000-U ﬂuorescent microscope,
and images were collected and quantiﬁed using Metamorph
4.0 software. For each yeast sample, at each time point ∼
750 cells of each type were scored for all or some of these
localization patterns: cytoplasmically diﬀuse, plasma mem-
brane, aggregate, membrane/diﬀuse, membrane/aggregate,
and endomembrane, endomembrane/aggregate, endomem-
brane/diﬀuse (bottom). All microscopy experiments were
conducted twice.
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